CBS 2019
CBSMD教育中心
English

肺动脉高压

科研文章

荐读文献

Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension Skeletal muscle mitochondrial oxidative phosphorylation function in idiopathic pulmonary arterial hypertension: in vivo and in vitro study 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study The association between body mass index and obesity with survival in pulmonary arterial hypertension Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension Clinical and genetic characteristics of pulmonary arterial hypertension in Lebanon Right ventricular stroke work correlates with outcomes in pediatric pulmonary arterial hypertension Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial 中国肺高血压诊断和治疗指南2018

Guideline2016 Jan 1;37(1):67-119.

JOURNAL:Eur Heart J. Article Link

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)

Galiè N, Humbert M, ESC Scientific Document Group. Keywords: Chronic thromboembolic pulmonary hypertension; Congenital heart disease; Connective tissue disease; Endothelin receptor antagonists; Guidelines; Heart failure; Left heart disease; Lung disease; Phosphodiesterase type 5 inhibitors; Prostacyclin analogues; Pulmonary arterial hypertension; Pulmonary hypertension; Respiratory failure

Full Text PDF